Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Brandl

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Research|October 31, 2019
Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse EventsMatthias Klinger, Gerhard Zugmaier, Virginie Nägele, et al.
Cancer Immunology, Immunotherapy : CII|February 21, 2007
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody constructChristian Brandl, Cornelia Haas, Sandrine d'Argouges, et al.
Nature Nanotechnology|July 24, 2023
Dynamic topological domain walls driven by lithium intercalation in grapheneYukihiro Endo, Xue Yan, Meng Li, et al.
Leukemia Research|October 7, 2008
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cellsSandrine d'Argouges, Sandra Wissing, Christian Brandl, et al.
Cancer Immunology, Immunotherapy : CII|July 21, 2005
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody constructBernd Schlereth, Cornelia Quadt, Torsten Dreier, et al.
Molecular Cancer Therapeutics|August 11, 2021
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) MoleculeElizabeth Pham, Matthias Friedrich, Famke Aeffner, et al.
Molecular Cancer Therapeutics|October 9, 2012
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigensMatthias Friedrich, Tobias Raum, Ralf Lutterbuese, et al.
Blood|May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabMatthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.
Frontiers in Immunology|November 9, 2023
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapyHweixian Leong Penny, Kelly Hainline, Nathaniel Theoharis, et al.
Science (New York, N.Y.)|August 16, 2008
Tumor regression in cancer patients by very low doses of a T cell-engaging antibodyRalf Bargou, Eugen Leo, Gerhard Zugmaier, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Research|October 31, 2019
Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse EventsMatthias Klinger, Gerhard Zugmaier, Virginie Nägele, et al.
Cancer Immunology, Immunotherapy : CII|February 21, 2007
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody constructChristian Brandl, Cornelia Haas, Sandrine d'Argouges, et al.
Nature Nanotechnology|July 24, 2023
Dynamic topological domain walls driven by lithium intercalation in grapheneYukihiro Endo, Xue Yan, Meng Li, et al.
Leukemia Research|October 7, 2008
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cellsSandrine d'Argouges, Sandra Wissing, Christian Brandl, et al.
Cancer Immunology, Immunotherapy : CII|July 21, 2005
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody constructBernd Schlereth, Cornelia Quadt, Torsten Dreier, et al.
Molecular Cancer Therapeutics|August 11, 2021
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) MoleculeElizabeth Pham, Matthias Friedrich, Famke Aeffner, et al.
Molecular Cancer Therapeutics|October 9, 2012
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigensMatthias Friedrich, Tobias Raum, Ralf Lutterbuese, et al.
Blood|May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabMatthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.
Frontiers in Immunology|November 9, 2023
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapyHweixian Leong Penny, Kelly Hainline, Nathaniel Theoharis, et al.
Science (New York, N.Y.)|August 16, 2008
Tumor regression in cancer patients by very low doses of a T cell-engaging antibodyRalf Bargou, Eugen Leo, Gerhard Zugmaier, et al.
Pageof 2